At RJH Biosciences, we develop non-viral, polymer-based nucleic acid delivery systems designed for efficient transfection of primary and hard-to-transfect cells. Our platform enables robust delivery of a range of nucleic acids with consistent performance across diverse primary cells. The RJH reagents achieve strong and reproducible gene expression in primary and murine cell models, outperforming commercial comparators. This shows the broad applicability of RJH materials for research and translational applications.
Consistent mRNA Expression in PBMCs
GFP mRNA expression in primary human PBMCs. Peripheral blood mononuclear cells (PBMCs) from two healthy donors were transfected with GFP mRNA using RJH transfection reagents: mRNA-Fect Ultra and mRNA-Fect Ultra/Trans Booster. Additionally, jetMESSENGER® transfection reagent from another commercial source was used. GFP expression was analyzed 24 hours post-transfection using flow cytometry, with the results presented as mean fluorescence intensity. The RJH formulations demonstrated strong mRNA expression across both donor samples.
Efficient siRNA and pDNA Tranfection in Primary Cells
Broad nucleic acid delivery in different primary cells.
(A) siRNA delivery in primary murine bone marrow stromal cells (BMSCs). BMSCs (n=3) were transfected with FAM-labeled siRNA using our material, Leu-Fect, alongside a commercial comparator, Lipofectamine™ RNAiMAX. Cellular siRNA uptake was assessed 24 hours post-transfection by flow cytometry. C, Control group. (B) pDNA transfection in primary human cord blood cells. Cells were transfected with GFP pDNA with our transfection reagent, ALL-Fect. Lipofectamine™ 2000 was used from another commercial comparator. GFP expression was evaluated 24 hours post-transfection by flow cytometry. C, Control group.
About RJH Biosciences
RJH Biosciences specializes in lipopolymer-based transfection reagents for efficient siRNA, mRNA, and DNA delivery across a wide range of biological systems. Our platforms are optimized for high-throughput screening, functional genomics, and RNA interference (RNAi) applications, enabling reliable gene modulation in cell lines, primary cells, and in vivo models.
With a focus on reproducibility, scalability, and low cytotoxicity, RJH supports researchers in accelerating drug discovery, target validation, and therapeutic development through customizable transfection solutions.
